共 50 条
- [41] 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study[J]. CANCER RESEARCH, 2020, 80 (04)Stavraka, CharaEvans, T. R. JeffryDunlop, JoannaEarl, HelenaCameron, David A.Coleman, Robert E.Perren, TimothyLeonard, Robert C. F.Mansi, Janine L.
- [42] Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study[J]. Breast Cancer Research and Treatment, 2010, 122 : 787 - 794Janine L. MansiAnn YellowleesJulian LipscombeHelena M. EarlDavid A. CameronRobert E. ColemanTimothy PerrenChristopher J. GallagherMary QuigleyJohn CrownAlison L. JonesMartin HighleyRobert C. F. LeonardT. R. Jeffry Evans
- [43] Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study[J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) : 787 - 794Mansi, Janine L.Yellowlees, AnnLipscombe, JulianEarl, Helena M.Cameron, David A.Coleman, Robert E.Perren, TimothyGallagher, Christopher J.Quigley, MaryCrown, JohnJones, Alison L.Highley, MartinLeonard, Robert C. F.Evans, T. R. Jeffry
- [44] A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer[J]. ANNALS OF ONCOLOGY, 2002, 13 (08) : 1225 - 1235Perez, EAGeeraerts, LSuman, VJAdjei, AABaron, ATHatfield, AKMaihle, NMichalak, JCKuross, SAKugler, JWLafky, JMIngle, JN
- [45] Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC)[J]. ANNALS OF ONCOLOGY, 2004, 15 : 57 - 57Ahn, Joong-BaeOh, Jung-HyeKwon, YoungmeeChung, Ki-WookKang, Han-SungShin, Kyung HwanKim, Eun-ALee, Eun SookRo, Jungsil
- [46] Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer[J]. ANNALS OF ONCOLOGY, 2004, 15 (10) : 1527 - 1534Chan, SDavidson, NJuozaityte, EErdkamp, FPluzanska, AAzarnia, NLee, LW
- [47] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study[J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5Slamon, DEiermann, WRobert, NPienkowski, TMartin, MPawlicki, MChan, ASmylie, MLiu, MFalkson, CPinter, TFornander, TShiftan, TValero, VVon Minckwitz, GMackey, JTabah-Fisch, JBuyse, MLindsay, MARiva, ABee, VPegram, MPress, MCrown, J
- [49] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)[J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595Lee, Sang GyuJee, Young GeonChung, Hyun ChulKim, Sung-BaeRo, JungsilIm, Young-HyuckIm, Seock-AhSeo, Jae Hong
- [50] COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER[J]. VALUE IN HEALTH, 2009, 12 (03) : A45 - A45Jones, S.Chen, L.Tangirala, M.Asmar, L.Airia, P.Thompson, M. F.